Reproductive Medicine Associates of New Jersey, Morristown, NJ 07960, USA.
Semin Reprod Med. 2012 Jun;30(3):236-42. doi: 10.1055/s-0032-1311526. Epub 2012 May 14.
Interest in using aneuploidy screening to select embryos has been renewed with the introduction of new methods for comprehensive chromosome screening (CCS) that evaluate all 24 chromosomes. With a series of experiments providing level I evidence of accuracy, reliability, safety, predictive value, and clinical efficacy, CCS-based selection of a single euploid blastocyst may provide an opportunity to finally realize the potential benefits and practical application of elective single embryo transfer. Furthermore, by incorporating CCS into research and development to control for chromosomal contribution to reproductive potential, additional biomarkers may now be more readily identified that help to further enhance the efficacy of embryo selection technology. This review describes the critical components of a valid CCS embryo selection methodology and discusses the limitations and opportunities for future routine application in reproductive medicine.
利用非整倍体筛查来选择胚胎的兴趣随着综合染色体筛查（CCS）新方法的引入而重新燃起，该方法可评估所有 24 条染色体。一系列实验提供了 I 级准确性、可靠性、安全性、预测值和临床疗效的证据，基于 CCS 选择单个整倍体囊胚可能为最终实现选择性单胚胎移植的潜在益处和实际应用提供了机会。此外，通过将 CCS 纳入研究和开发以控制对生殖潜能的染色体贡献，现在可能更容易识别出其他生物标志物，从而进一步提高胚胎选择技术的疗效。本文描述了有效的 CCS 胚胎选择方法学的关键组成部分，并讨论了其在生殖医学中未来常规应用的局限性和机遇。
